OCT 23, 2020 6:00 AM PDT

Follow Your Heart: A Genetic Predictor of Cardiovascular Disease

WRITTEN BY: Tara Fernandez

Cardiovascular disease is the leading cause of death globally, resulting in the loss of nearly 18 million lives each year. Earlier interventions through drug prescriptions or lifestyle changes are our best hope for saving lives. Researchers at Massachusetts General Hospital have identified a biomarker in the blood that can help pinpoint individuals most at risk of developing heart disease earlier, allowing them to make these changes sooner. The protein, called lipoprotein(a), can be measured easily using standard serological or genetic tests.

Lipoprotein(a) is a type of low-density lipoprotein (LDL)-like lipoprotein. Unlike LDL cholesterol (often referred to as the “bad” cholesterol due to its link with an increased risk of getting a heart attack or stroke), lipoprotein(a) has, until now, been under-recognized as a biomarker for heart disease. As a result, its blood levels are rarely measured as part of a patient’s blood work.

Pradeep Natarajan, MD is the lead investigator and senior author of the study that aims to shift the focus onto lipoprotein(a) as a valuable genetic test for cardiovascular disease. “Our work demonstrates that genetic risk scoring of lipoprotein(a) offers risk prediction of atherosclerotic cardiovascular disease that’s comparable to directly measured lipoprotein(a),” said Natarajan.

“We learned that genetic determinants of elevated lipoprotein(a) may help identify the most effective medication regimen for cardiovascular disease prevention.”

A person’s lipoprotein(a) levels are heavily influenced (up to 95 percent) by genetics as opposed to diet and physical activity levels. Those with a genetic predisposition to have over 50 milligrams per deciliter lipoprotein(a) concentrations in the blood, are 50 percent more likely to develop cardiovascular conditions.

“Using genetic factors enhances our ability to identify at-risk individuals for cardiovascular disease who could benefit from earlier preventive strategies,” explained Natarajan, who added, “At the same time, genetic testing could help identify candidates for clinical trials who are critical to discovering innovative new therapies to address conditions like elevated lipoprotein(a) and related cardiovascular disease risks.”

 

 

Sources: Massachusetts General Hospital, JAMA Cardiology.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
NOV 07, 2020
Neuroscience
Device Measures Stress Hormones with Earwax
NOV 07, 2020
Device Measures Stress Hormones with Earwax
Researchers from University College London and King’s College London in the UK have developed a device that can me ...
NOV 17, 2020
Clinical & Molecular DX
Tumor Stiffness Linked to Its Aggressiveness
NOV 17, 2020
Tumor Stiffness Linked to Its Aggressiveness
  As tumors grow, tiny areas at their cores are found to become stiff prior to metastasis, or the spread of cancer ...
DEC 19, 2020
Clinical & Molecular DX
Urine Tests Sets Parents' Minds at Ease in Minutes After a Miscarriage Threat
DEC 19, 2020
Urine Tests Sets Parents' Minds at Ease in Minutes After a Miscarriage Threat
Researchers have developed a chip-based test that can determine pregnancy outcomes after the signs of a possible miscarr ...
JAN 22, 2021
Clinical & Molecular DX
Breast Cancer's Nasty Nine Revealed
JAN 22, 2021
Breast Cancer's Nasty Nine Revealed
Calculating an individual’s risk of developing breast cancer isn’t easy. There’s a complex interplay b ...
JAN 26, 2021
Clinical & Molecular DX
Prostate Cancer Screening: No More False Positives
JAN 26, 2021
Prostate Cancer Screening: No More False Positives
A new diagnostic test powered by artificial intelligence has been found to detect prostate cancer markers in urine sampl ...
FEB 11, 2021
Clinical & Molecular DX
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
FEB 11, 2021
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
Only around half of women diagnosed with breast cancer will benefit from hormonal therapy, a cancer treatment that adds, ...
Loading Comments...